Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CEPHULAC vs COLYTE WITH FLAVOR PACKS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Lactulose, a synthetic disaccharide, is not absorbed from the gastrointestinal tract. It is metabolized by colonic bacteria to form short-chain fatty acids (e.g., lactic, acetic, formic acids), which acidify the colonic contents. In hepatic encephalopathy, the acidic environment converts ammonia (NH3) to ammonium (NH4+), which is poorly absorbed and excreted in feces. Additionally, the osmotic effect of lactulose draws water into the colon, softening stools and increasing bowel movements.
Colyte is an isotonic solution containing polyethylene glycol 3350 and electrolytes. It acts as an osmotic laxative by retaining water in the colon through non-absorbable polyethylene glycol, resulting in bowel evacuation. The electrolytes prevent significant fluid and electrolyte shifts.
Treatment of constipation,Hepatic encephalopathy (portal-systemic encephalopathy) including the prevention and treatment of coma
Bowel cleansing prior to colonoscopy or barium enema
30-45 m L (6.67-10 g lactulose) orally 3-4 times daily for constipation; for hepatic encephalopathy, 30-45 m L orally 3-4 times daily titrated to produce 2-3 soft stools per day, or 300 m L in 700 m L of water or saline as retention enema for 30-60 min every 4-6 hours.
Adults: 4 liters of reconstituted solution administered orally or via nasogastric tube at a rate of 240 m L every 10 minutes, given as a single dose or in divided doses for colonoscopy preparation.
Terminal elimination half-life is 7-10 hours (renal impairment: prolonged); systemic absorption is minimal (<3%) after oral administration, so half-life reflects clearance of absorbed fraction.
Not applicable (non-absorbed; no systemic absorption, thus no elimination half-life in plasma).
Not absorbed; metabolized by colonic bacteria (e.g., Lactobacillus, Bacteroides) to low molecular weight organic acids.
Polyethylene glycol 3350 is minimally absorbed and not metabolized; it is excreted unchanged in feces. Electrolytes are absorbed and metabolized normally.
Primarily renal (20-30% as unchanged drug) and fecal (up to 70% as unmetabolized drug via biliary elimination; following gastric acid-mediated degradation, only 5-10% reaches urine as intact lactulose; hepatic metabolism is negligible).
Primarily fecal (100%) as non-absorbed oral solution; negligible renal or biliary elimination.
Negligible (<5%): lactulose does not bind significantly to albumin or other plasma proteins due to its hydrophilic nature.
Not applicable (non-absorbed; no systemic exposure).
0.5-1.0 L/kg (estimated from systemic absorption studies; limited data due to minimal absorption; reflects distribution largely into extracellular water).
Not applicable (non-absorbed; no systemic distribution).
Oral: <3% (due to poor absorption and extensive metabolism by colonic bacteria; most of the drug remains in the gut lumen). Rectal: similar to oral, as systemic absorption is minimal.
Oral: negligible systemic bioavailability (<0.1%) due to minimal absorption of polyethylene glycol and electrolytes.
No dose adjustment required for renal impairment as lactulose is minimally absorbed and primarily acts locally in the colon.
No dose adjustment required for renal impairment; however, use with caution in patients with severe renal impairment (GFR <30 m L/min) due to risk of fluid and electrolyte abnormalities.
Not specifically adjusted based on Child-Pugh score; dose is titrated to achieve desired stool frequency; caution in severe hepatic impairment due to risk of electrolyte disturbances.
No specific dose adjustment for hepatic impairment; use standard dosing with caution in severe liver disease due to potential fluid shifts.
Infants: 2.5-10 m L/day in divided doses; older children: 10-25 m L/day; adolescents: 15-30 m L/day; all for constipation; for hepatic encephalopathy, doses as low as 5-10 m L 3-4 times daily with dose adjusted to produce 2-3 soft stools per day.
Pediatric patients: 25-40 m L/kg/hour until rectal effluent is clear; maximum 4 liters total. Safety and efficacy not established for children under 6 months.
Initiate at lower end of dosing range (15-30 m L/day) due to increased risk of dehydration and electrolyte imbalance; monitor for diarrhea and adjust accordingly.
Elderly: Consider reduced volume (e.g., 2-3 liters) and slower administration rate (e.g., 240 m L every 20 minutes) to mitigate risk of aspiration and electrolyte imbalance.
None
WARNING: SERIOUS FLUID AND ELECTROLYTE ABNORMALITIES, SEIZURES, AND CARDIAC ARRHYTHMIAS. Use with caution in patients at risk for these conditions. Monitor fluid and electrolyte status.
Electrolyte imbalance with prolonged use, especially in debilitated patients,Diarrhea may cause fluid and electrolyte loss,Galactose intolerance (contraindicated in patients requiring low galactose diet due to lactose content in some preparations),Monitor serum electrolytes in patients receiving high doses for hepatic encephalopathy
Risk of aspiration, especially in patients with impaired gag reflex or reduced level of consciousness,Fluid and electrolyte disturbances (e.g., hyponatremia, hypokalemia) may occur; monitor in patients with renal or hepatic impairment, heart failure, or those taking diuretics or other drugs affecting electrolytes,Seizures and cardiac arrhythmias have been reported, often in patients with electrolyte imbalances or taking medications that lower seizure threshold,Mucosal ulcerations may occur; avoid use in patients with active inflammatory bowel disease or toxic megacolon,Arrhythmias (e.g., atrial fibrillation, QT prolongation) have been reported,Upper GI bleeding or obstruction; contraindicated in gastric retention or obstruction
Patients requiring a low-galactose diet (lactulose contains galactose and lactose),Intestinal obstruction,Suspected gastrointestinal obstruction or perforation
Gastrointestinal obstruction or ileus,Gastric retention or perforation,Bowel perforation,Toxic colitis or toxic megacolon,Hypersensitivity to any component
No specific food interactions. Avoid concurrent use with other laxatives unless directed. High-fiber foods may enhance effect; ensure adequate fluid intake.
Avoid all solid foods and dairy products during bowel preparation. Only clear liquids (e.g., water, clear broth, black coffee, tea without milk, clear fruit juices without pulp, gelatin) are permitted. Do not consume red or purple liquids as they may be mistaken for blood during colonoscopy. Alcohol should be avoided for at least 24 hours prior to the procedure.
Lactulose (CEPHULAC) is not absorbed systemically; therefore, fetal exposure is negligible. Animal studies have not shown teratogenic effects. In clinical practice, no fetal risks have been identified in any trimester.
Pregnancy Category C. No adequate well-controlled studies in pregnant women. Polyethylene glycol (PEG) is not systemically absorbed; minimal fetal exposure expected. Electrolyte shifts could theoretically affect fetal fluid balance, but no known teratogenicity. First trimester: low risk based on lack of systemic absorption. Second/third trimester: theoretical risk of maternal electrolyte imbalance affecting fetal homeostasis, though no specific fetal adverse effects reported.
Lactulose is not excreted into breast milk due to minimal systemic absorption. It is considered compatible with breastfeeding. M/P ratio: Not applicable (negligible absorption).
PEG is not absorbed systemically, thus minimal excretion into breast milk. M/P ratio not applicable/unknown. Considered compatible with breastfeeding as a bowel preparation, but caution with large volumes may alter maternal fluid/electrolyte status, indirectly affecting milk production or composition. Use only if clearly needed.
No dose adjustment required. Pharmacokinetics are unchanged in pregnancy due to lack of systemic absorption. Standard dosing of 15-30 m L (10-20 g) once daily, up to 60 m L/day in divided doses, is appropriate.
No specific pharmacokinetic changes in pregnancy requiring dose adjustment due to lack of systemic absorption. However, decreased gastrointestinal motility in pregnancy may prolong colonic transit time; no dose change recommended but monitor for tolerance. Use standard dosing (e.g., 4L in split dose) as in non-pregnant adults, with attention to hydration.
Cephulac (lactulose) is a non-absorbable disaccharide used for constipation and hepatic encephalopathy. In hepatic encephalopathy, titrate to produce 2-3 soft stools per day. Monitor serum electrolytes, especially in elderly or renal impairment. Onset of action for constipation may be 24-48 hours. Do not confuse with other lactose-containing products.
Colyte with Flavor Packs is a polyethylene glycol 3350-based osmotic laxative used for bowel cleansing prior to colonoscopy. Ensure adequate hydration before, during, and after administration. Do not use flavor packs containing aspartame in patients with phenylketonuria. Monitor for electrolyte imbalances in patients with renal impairment or those on diuretics. Discontinue if severe bloating, abdominal pain, or vomiting occurs.
Take exactly as prescribed; may take 24-48 hours to produce a bowel movement.,For hepatic encephalopathy, maintain 2-3 soft stools daily; do not skip doses.,May cause bloating, gas, or cramping initially; usually resolves.,Do not take other laxatives without consulting your doctor.,Report severe diarrhea, vomiting, or muscle cramps to your healthcare provider.
Do not eat any solid food after starting the preparation; only clear liquids are allowed.,Mix the powder with water as directed and refrigerate to improve taste.,Drink the entire solution at the prescribed rate; set a timer if needed.,Expect watery stools; stay near a bathroom during the cleansing process.,Do not add extra flavorings or sweeteners unless provided in the pack.,Contact your doctor if you experience severe nausea, vomiting, or inability to keep the solution down.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CEPHULAC vs COLYTE WITH FLAVOR PACKS, answered by our medical review team.
CEPHULAC is a Laxative that works by Lactulose, a synthetic disaccharide, is not absorbed from the gastrointestinal tract. It is metabolized by colonic bacteria to form short-chain fatty acids (e.g., lactic, acetic, formic acids), which acidify the colonic contents. In hepatic encephalopathy, the acidic environment converts ammonia (NH3) to ammonium (NH4+), which is poorly absorbed and excreted in feces. Additionally, the osmotic effect of lactulose draws water into the colon, softening stools and increasing bowel movements.. COLYTE WITH FLAVOR PACKS is a Osmotic Laxative that works by Colyte is an isotonic solution containing polyethylene glycol 3350 and electrolytes. It acts as an osmotic laxative by retaining water in the colon through non-absorbable polyethylene glycol, resulting in bowel evacuation. The electrolytes prevent significant fluid and electrolyte shifts.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CEPHULAC and COLYTE WITH FLAVOR PACKS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CEPHULAC is: 30-45 m L (6.67-10 g lactulose) orally 3-4 times daily for constipation; for hepatic encephalopathy, 30-45 m L orally 3-4 times daily titrated to produce 2-3 soft stools per day, or 300 m L in 700 m L of water or saline as retention enema for 30-60 min every 4-6 hours.. The standard adult dose of COLYTE WITH FLAVOR PACKS is: Adults: 4 liters of reconstituted solution administered orally or via nasogastric tube at a rate of 240 m L every 10 minutes, given as a single dose or in divided doses for colonoscopy preparation.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CEPHULAC and COLYTE WITH FLAVOR PACKS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CEPHULAC is classified as Category C. Lactulose (CEPHULAC) is not absorbed systemically; therefore, fetal exposure is negligible. Animal studies have not shown teratogenic effects. In clinical practice, no fetal risks . COLYTE WITH FLAVOR PACKS is classified as Category C. Pregnancy Category C. No adequate well-controlled studies in pregnant women. Polyethylene glycol (PEG) is not systemically absorbed; minimal fetal exposure expected. Electrolyte sh. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.